Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction
about
Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low- and middle-income countriesInhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelEvaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine.Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?Routinely vaccinating adolescents against meningococcus: targeting transmission & diseaseMeningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the NetherlandsThe impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Glycoconjugate vaccines.Meningococcal vaccines: current issues and future strategies.Evolving meningococcal immunization strategies.Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.Increased incidence of invasive meningococcal disease of serogroup C / clonal complex 11, Tuscany, Italy, 2015 to 2016.What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK Experience.Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.The endgame for serogroup a meningococcal disease in Africa?Editorial commentary: fifteen years of protection by meningococcal C conjugate vaccines: lessons from disease surveillance.
P2860
Q28078813-5B8B21DF-AB6A-4798-A236-B627A6A4B3D4Q33602953-B354E541-F3DB-4565-AFF5-26FB925B4C96Q33959308-AE1AD4C5-0293-463D-9410-8AC44D99A7C2Q34033849-0FA24D54-3606-4534-992E-489B162AC0F2Q35887266-86647A9D-B122-4234-ACF6-2ACF6734563BQ36825737-7C3678E4-AFC8-436A-8708-E3B46A7DC959Q36891586-5D7D7318-7CAF-4A1A-A327-98D246E54175Q37037419-5D990A04-90C2-44EB-AE3E-3284C4688514Q38044755-E6C126B6-6055-4DA0-AEA0-25A593565D49Q38120493-2412214A-7083-48B5-89E7-ED41F7EC9A94Q38286082-A1F73246-C059-4308-8243-0AC96D45DA12Q38791439-D045B001-D466-48BD-89B9-C8AD86D28A95Q39872151-F9D29897-D40C-411C-A9A7-33676C24ED4DQ40778094-C362B42C-7072-4180-9A63-DDB4DDA89340Q42255158-52D82260-252E-4BF7-802F-E6BBA7B1F108Q42577186-C2D5D1D4-03FD-4ABF-B3DA-4A9D2A2C89CAQ42937602-64EB4D4E-D879-4007-B520-8559D87F75A1
P2860
Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prevalence of serum bactericid ...... ade after vaccine introduction
@ast
Prevalence of serum bactericid ...... ade after vaccine introduction
@en
type
label
Prevalence of serum bactericid ...... ade after vaccine introduction
@ast
Prevalence of serum bactericid ...... ade after vaccine introduction
@en
prefLabel
Prevalence of serum bactericid ...... ade after vaccine introduction
@ast
Prevalence of serum bactericid ...... ade after vaccine introduction
@en
P2093
P2860
P356
P1476
Prevalence of serum bactericid ...... ade after vaccine introduction
@en
P2093
David A Ishola
Helen Findlow
Jamie Findlow
Mary E Ramsay
P2860
P304
P356
10.1128/CVI.05655-11
P577
2012-05-30T00:00:00Z